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ArthritisDuring chondrogenesis, complex intracellular signalling pathways regulate an intricate series of events including
condensation of chondroprogenitor cells and nodule formation followed by chondrogenic differentiation. Revers-
ible phosphorylation of key target proteins is of particular importance during this process. Among protein kinases
known to be involved in these pathways, protein kinase C (PKC) subtypes play pivotal roles. However, the precise
function of PKC isoenzymes during chondrogenesis and in mature articular chondrocytes is still largely unclear. In
this review, we provide a historical overview of how the concept of PKC-mediated chondrogenesis has evolved,
starting from the ﬁrst discoveries of PKC isoform expression and activity. Signalling components upstream and
downstream of PKC, leading to the stimulation of chondrogenic differentiation, are also discussed. Although it is
evident that we are only at the beginning to understand what roles are assigned to PKC subtypes during chondro-
genesis and how they are regulated, there are many yet unexplored aspects in this area. There is evidence that
calcium signalling is a central regulator in differentiating chondroprogenitors; still, clear links between intracellular
calcium signalling and prototypical calcium-dependent PKC subtypes such as PKCalpha have not been established.
Exploiting putative connections and shedding more light on how exactly PKC signalling pathways inﬂuence
cartilage formation should open new perspectives for a better understanding of healthy as well as pathological
differentiation processes of chondrocytes, and may also lead to the development of novel therapeutic approaches.
© 2014 The Authors. Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY
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Cells of multicellular organisms are constantly exposed to the extra-
cellular environment and receive a plethora of chemical signals at the
same time. Among these signals are various endocrine, paracrine,
juxtacrine and autocrine factors including hormones (e.g. somatotropin
and insulin); cytokines, growth and differentiation factors such as bone
morphogenic proteins (BMPs), epidermal, ﬁbroblast or insulin-like
growth factors (EGF, FGF, IGF), or transforming growth factors (TGFs);
aswell asmorphogens, e.g. retinoic acid,Wingless (Wnt), sonic hedgehog
(Shh), or indian hedgehog (Ihh). These molecules are bound to plasma
membrane or intracellular receptors and interpreted by complexmolecu-
lar pathways that utilise speciﬁc combinations of a cell or tissue-speciﬁc
signalling toolkit, and by eventually converging on transcription factors
they often induce changes in gene expression. These signals are required
to adjust the cellular metabolism to the needs of the tissue and/or organ-
ism, or to determine decisions that affect the fate of cells: proliferation,
differentiation, or apoptosis [1].
This is particularly true for differentiating embryonic tissues, where
individual cells are required to act in an extraordinarily co-ordinated
way both temporally and spatially to ensure all tissue and cell types
are formed appropriately. This process is known as speciﬁcation and
differentiation, which involves the expression of unique cellular func-
tions that enable individual cells to contribute to the operation and
needs of different tissues, organs and organ systems [2]. For differentia-
tion to take place, a carefully orchestrated sequence of events is required
that is tightly regulated by complex signalling pathways.
2. Chondrogenesis is regulated by a complex interplay between
many factors
Cartilage formation, one of the earliestmorphogenetic events during
embryonic development, is a highly organised multistep process that
involves condensation of chondroprogenitor cells, differentiation into
chondroblasts and then chondrocytes, and the transformation of
chondrogenic tissues into skeletal structures (recently reviewed by
[3]). The process is characterised by substantial changes in the shape
of chondroprogenitor cells, which requires transition to a spherical
chondroblast and chondrocyte-like morphology from the elongated
ﬁbroblast-like shape [4]. Although the main steps of chondrogenesis
that takes place in embryonic limb bud-derived micromass cultureshave been partially mapped, there are still many yet unresolved
questions. De facto chondrogenesis is preceded by the appearance of
precartilaginous condensations, brought about by enhanced prolifera-
tion and active migration of chondroprogenitors; these condensations
enable the establishment of cell–cell and cell–matrix interactions
(via gap junction, N-cadherin and N-CAM and through integrins,
respectively) that initiate inter- and intracellular signalling events [5].
Apart from cell adhesion molecules, interactions of various proteins
including FGFs, TGFs, BMPs, Wnt, Shh, and products of the homeobox
(Hox) genes are also required [6]. Acting through their receptors,
these factors activate their downstream targets that are essential for
initiation and maintenance of the chondrocyte phenotype.
Apart from soluble factors, macromolecules of the developing extra-
cellular matrix (ECM) itself including collagen type II, hyaluronan, the
large aggregating proteoglycan (PG) aggrecan, or ﬁbronectin can also
act as signalling molecules [6]. For example, binding of integrin α5β1
(the ﬁbronectin-receptor) to its ligand initiates the establishment of
focal adhesions and leads to the activation of focal adhesion kinase
(FAK), which in turn interacts with the phosphoinositol-3 kinase
(PI-3K) and contributes to the activation of mitogen-activated protein
kinases (MAPK) [7]. The MAPK cascades play very important roles in
mediating the effects of extracellular signals to regulate a variety of
cellular functions, including proliferation, differentiation, and stress
responses. It has long been known that various MAPKs including the
extracellular signal-regulated kinase 1/2 (ERK1/2) and p38 regulate
chondrogenesis in chicken limb bud-derived micromass cultures; while
ERK1/2 was found to be a negative regulator, p38 is a positive regulator
of chondrogenesis as it modulates the expression of cell adhesion
molecules (e.g. N-cadherin, and integrin α5β1) at the post-precartilage
condensation stages [8]. Besides ERK1/2 and p38, the involvement of
the third MAPK pathway, the c-Jun N-terminal kinase (JNK) signalling
pathway,was also reported recently in thedifferentiation of chondrocytes
[9,10].
The cartilage-speciﬁc transcription factors Sox9, L-Sox5 and Sox6 that
are often referred to as the Sox-trio are essential for the expression of
ECM proteins (e.g. COL2A1, aggrecan core protein). The Sox transcription
factors, Sox9 in particular, are strongly expressed throughout chondro-
genesis as they are required for the initial steps of condensation and for
maintaining the chondroprogenitor phenotype of differentiatingmesen-
chymal cells [11]. Since the Sox9 transcription factor is indispensable to
chondrogenesis, many signalling pathways are known to converge on
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above-described pathways are central components of chondrogenesis,
their regulation is accomplished by other factors, such as Ser/Thr protein
kinases.
Protein kinase A (PKA) is among the earliest known regulators of
chondrogenesis; Solursh and co-workers reported that cyclic adenosine
monophosphate (cAMP) levels increased during the initial condensa-
tion of mouse and chick limb bud-derived mesenchymal cells cultured
in vitro [12]; furthermore, exogenous cAMP derivatives were shown to
enhance in vitro chondrogenesis [13]. These discoveries have led to
establishing a chondrogenesis-promoting role for PKA, which does not
only mediate the positive effects of BMP on chondrogenic differentia-
tion by phosphorylating Ser/Thr residues of key substrates [14] but
also regulates cAMP responsive genes via the cAMP response element
binding protein (CREB) that binds to CRE sites within promoters of
certain genes; for example, the Sox9 promoter itself is known to be
regulated by CREB [15]. Besides controlling its expression, PKA is also
known to phosphorylate the Sox9 protein (at Ser 211), which induces
its translocation into the nucleus and enhances its transcriptional
activity [16].
Apart from various protein kinases, phosphoprotein phosphatases
(PP) that counterbalance the effects of kinases are equally important
regulators of chondrogenesis. Our laboratory was the ﬁrst to demon-
strate that PP2A negatively regulates chondrogenic differentiation as
its inhibition with okadaic acid enhanced chondrogenesis viamodulat-
ing proliferation and cytoskeletal organisation in mesenchymal cells, as
well as through cross-talk with the PKA signalling pathway [17].
Furthermore, CREB was identiﬁed as one of the important common tar-
gets for the PP2A and PKA pathways whose phosphorylation status was
modiﬁed according to the actual balance between the two signalling
mechanisms [18]. We have recently demonstrated that cyclic mechani-
cal load exerts chondrogenesis-stimulating effects via opposing regula-
tion of PKA and PP2A signalling in micromass cultures of embryonic
chicken limb bud-derived differentiating chondroprogenitors [19]. The
Ca2+–calmodulin dependent PP2B (calcineurin), on the other hand, is
a positive regulator of chondrogenesis in chick limb bud-derived
micromass cultures, which exerts its chondro-stimulatory effects via
the ERK1/2 pathway [20].
Signalling events including extracellular soluble factors and cell
junction molecules that are reported to control various steps of chon-
drogenesis including condensation and changes in cell morphology
are shown in Fig. 1.Fig. 1.Main steps of chondrogenesis and the signalling pathways involved in its regulation. Cho
phology. During condensation, chondrogenic cells undergo extensive proliferation andmigration
BMP,Wnt), cell adhesionmolecules (N-CAM, N-cadherin, integrinα5β1) and intracellular signa
are required for this step. After the differentiation process has occurred, cells gain round mor
required for cartilage-speciﬁc ECM production and maintenance. In each step of chondrogenes
(FGF: ﬁbroblast growth factor; TGF-β: transforming growth factor beta; BMP: bonemorphogen
2A and2B; ERK1/2: extracellular signal regulated kinase; JNK: c-junN-terminal kinase; CREB: cA3. Protein kinase C: a versatile family of Ser/Thr kinases
Indeed, there is a complex synergism between signalling pathways
that control the molecular steps of chondrogenesis. Yoon and co-
workers reported that in chondrifyingmicromass cultures of embryonic
limb bud-derived mesenchymal cells, PKA regulates chondrogenesis by
activating PKCα [21]. Unlike PKA, PKC is a multigene family that
comprises a group of highly related Ser/Thr protein kinases, which
were ﬁrst identiﬁed almost 40 years ago by Nishizuka and colleagues
from bovine cerebellum [22]. PKC isoenzymes are highly conserved in
eukaryotes, ranging from a single isoform in the yeast (S. cerevisiae) to
12 isoforms in mammals and thus constitute ~2% of the human kinome
[23]. All PKC isoforms possess a highly conserved kinase domain at the
C-terminus that is linked to a much more divergent regulatory domain
at theN-terminus by a ﬂexible hinge region. Furthermore, all PKC isoen-
zymes contain a pseudosubstrate sequence that is present in their
regulatory domain; when the enzyme is inactive (auto-inhibited), the
pseudosubstrate region occupies the substrate-binding pocket in the
kinase domain.When PKC is activated, the appropriate secondmessen-
gers bind to the regulatory domain, displacing the pseudosubstrate
region from the active site. For relevant recent reviews, see [24] and
[25].
Based on their regulatory domains and activation mechanisms, the
PKC family can be divided into four structurally and functionally distinct
subgroups (Fig. 2). The classic PKCs (cPKCs) comprise PKCα, PKCβ and
PKCγ; these enzymes are activated by binding of diacylglycerol (DAG)
and phospholipids to their C1 domains, as well as Ca2+-dependent
binding of phospholipids to their C2 domains. The novel PKCs (nPKCs),
which include PKCδ, PKCε, PKCη and PKCθ, are similarly activated by
DAG and phospholipids, but they do not require Ca2+. The atypical
PKCs (aPKCs) comprise PKCι/PKCλ (the latter in mice) and PKCζ; they
do not require Ca2+ or DAG for their activation. Just like aPKCs,
members of the PKN subfamily (PKN1, PKN2 and PKN3) are allosterically
activated by their partners via interactions with speciﬁc motifs and
domains; for a review, see [26]. The fact that conventional PKCs require
Ca2+ for their activation has signiﬁcant consequences, as these enzymes
may be pivotal mediators of global as well as localised changes in
cytosolic Ca2+ levels [27]. In addition to these methods of activation,
other regulatory processes can inﬂuence the function of PKCs, including
phosphorylation. The varied mechanisms of activation, as well as the
modular nature of the PKC family allow PKC activity to be deployed
with versatile spatial and temporal speciﬁcity. As a result, the PKCndroprogenitor cells are initially loosely arranged with elongated mesenchymal cell mor-
, resulting in the formation of precartilaginous nodules. Soluble factors (such as FGF, TGF-β,
llingmolecules including ERK1/2, p38 and JNKMAPKs, PKA, PP2A and PP2B, as well as PKC
phology as a result of cytoskeletal rearrangement and acquire a gene expression pattern
is, PKC isoforms play essential roles in the signalling pathways. For details, please see text.
ic protein; PKA, PKC: protein kinase A and C; PP2A and PP2B: phosphoprotein phosphatase
MP-responsive element binding protein; NFAT: nuclear factor of activated T-lymphocytes).
Fig. 2. Schematic illustration of the domain structure of the PKC superfamily. PKCs consist of a conserved kinase domain (towards the C-termini) and more variable regulatory domains
(towards theN-termini)with a ﬂexible hinge region between them. PKC isoenzymes can be divided into four structurally and functionally distinct subgroups according to their regulatory
domains: classical isoforms (cPKC), novel isoforms (nPKC), atypical isoforms (aPKC) and the PKC-related kinases (PKN). Conserved region 1 (C1; shown in grey) can confer binding of DAG
and phospholipids; C2 (in light purple) functions as a Ca2+-dependent phospholipid bindingmodule. Note that the C2 domain in nPKC does not bind Ca2+. Tandem C1 domains (C1A and
C1B) are molecular sensors of PMA/DAG in cPKC and nPKC isoforms, whereas the single aPKC C1 domain does not bind DAG/PMA. Phox/Bem domain 1 (PB1; in dark blue) acts as a
dimerisation site with various proteins. Homology region 1 (HR1; in light blue) that is only present in PKN confers small-GTPase binding properties. PKCs are regulated by auto-
inhibition through their pseudosubstrate sites (PS; in ultramarine) that binds to the substrate-bindingpocket in theC4 kinase domain (in purple).When the regulatory domain is recruited
to the plasma membrane through Ca2+, phospholipid and DAG, autoinhibition is relieved.
Adapted from [25] and [26].
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transduction pathways in a plethora cell types. PKC contributes to the
regulation of almost every aspect of cells, ranging from migration,
secretion, cell–cell connections, polarity, cell proliferation and cell
death, gene transcription and translation, cell morphology, regulation
of ion channels and receptors, and differentiation [24].
4. PKC is a quintessential regulator of chondrogenesis
4.1. Early results with administration of phorbol esters or PKC inhibitors
Initially, the majority of studies aiming at identifying the role of PKC
enzymes in chondrogenesis involved the use of tumour promoter
phorbol esters (e.g.phorbol-12-myristate-13-acetate, PMA). Bymimick-
ing DAG and binding to the C1 domain, these compounds are potent ac-
tivators of PKC. However, as PMA irreversibly activates PKC isoenzymes,
it does not perfectly represent the transient activation induced by DAG.
Furthermore, chronic exposure to these compounds downregulates
PKCs, which further complicates data interpretation.
According to the ﬁrst report in this ﬁeld from 1977 by Paciﬁci and
Holtzer, treatment of chondroblasts with PMA resulted in a rapid
morphological change; i.e. chondroblasts have lost their polygonal
morphology and at the same time ceased to synthesise sulphated ECM
components [28]. They also reported that the observed negative effect
was reversible if cellswere exposed to PMA for up to 72 h only. However,
longer-term treatment with PMA induced irreversible dedifferentiation
[28]. Several years later, these initial results have been conﬁrmed by
another group who also observed that treatment with PMA reversibly
inhibited chondrogenesis and inﬂuenced synthesis of ECM components
[29]. Furthermore, PMA-treated limb bud-derived mesenchymal cells
retained a ﬂattened, ﬁbroblast-likemorphology and failed to accumulate
type II collagen and other cartilage ECM components [30]. In view of the
pronounced inhibitory effect of PMA on chondrogenic differentiation
in vitro, these preliminary results provided indirect evidence that PKCs
might play a positive role in chondroblast differentiation and function.
The results of Garrison and co-workers shedmore light on how PMA
exerted its effects on chondrogenesis [31]. They compared the effects of
PMA to that of bryostatin I, a compound that also activates PKC and
binds competitively to the putative ‘PMA receptor’, without inﬂuencing
cell differentiation. According to their results, treatment of 4-day-old
chick limb bud-derived micromass cultures with PMA markedly
reduced cartilage formation; however, co-administration of bryostatin
I and PMA at equimolar concentrations prevented the inhibitory effect
of PMA on chondrogenesis, which has led to the conclusion that activa-
tion and/or downregulation of PKC alone cannot account for the effects
of PMA. Nevertheless, by altering the time of PMA exposure they could
establish the time frame andmechanism of its action; they demonstrat-
ed that PMA inhibited chondrocyte phenotypic expression, rather thancell commitment, as early exposure to PMA (during chondrocytic
commitment, i.e. in the ﬁrst 48 h) had little inhibitory effect, whereas
post-commitment exposure (during 0–96 h of culturing) caused a
strong inhibition of matrix synthesis [31].
The ﬁndings of Biddulph and Dozier provided further evidence on
the involvement of pathways triggered by phorbol esters in
chondrogenic differentiation [32]. In that study, the effects of the
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)were inves-
tigated on chondrogenesis in high density cultures (HDC) established
from chick limb bud-derived mesenchymal cells and also found that
TPA completely blocked chondrogenesis when administered during
the ﬁrst 4 culturing days. Furthermore, they also measured prostaglan-
din E2 (PGE2) and cAMP concentrations and established that both
parameters were altered by TPA treatment relative to untreated control
cultures. In TPA-treated HDC both PGE2 and cAMP levels increased
progressively during the 6-day-long culturing period in contrast to an
initial increase followed by a steady decline in untreated colonies [32].
The authors concluded that PGE2 and cAMP-independent regulatory
pathway(s) might be present in differentiating chondroprogenitor
cells. The same results were published by a different group in 1990
[33]; moreover, they conﬁrmed the chondro-inhibitory effect of TPA
by proteoglycan staining procedures as well as RNA hybridisation to
cDNA probes speciﬁc for cartilage ECM components. Furthermore, the
effect of TPA was found to depend on initial plating density; at high
density, TPA inhibited cell proliferation, whereas at low density, cell
proliferation was stimulated by TPA. Once again, these results showed
that the effects of phorbol esters on chondrogenesis are largely indirect;
they possibly act by modulating cell proliferation [33].
In 1994, Ferrari and co-workers continued to study the effects of
phorbol esters on chondrogenesis and reported that under the effect of
TPA limb bud-derived mesenchymal cells exhibited dysregulated
expression of the homeobox gene Msx1, implicated to suppress
chondrogenic differentiation and maintenance of undifferentiated
condition of chondroprogenitors [34]; furthermore, the formation of
extensive gap junctions that normally occurs at the onset of chondrogen-
esis also failed to occur [35]. From these results the authors concluded
that the chondro-suppressive effect of phorbol esters might stem from
their ability to modulate the expression of key regulatory genes, as well
as to interfere with the intercellular communication involved in the for-
mation of differentiated chondrocytes.
4.2. Implications of PKC activity for chondrogenesis
It was not until 1988 that an active regulatory role for PKCs has
been implicated in mediating insulin-like growth factor 1 (IFG-1)
induced metabolic and mitogenic effects in isolated articular
chondrocytes [36]. In that paper, the authors described that the effects
of IGF-1, i.e. it enhanced sulphate and 3H-thymidine incorporation,
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that both effects could be blocked by the PKC inhibitor compound H7
[1-5(isoquinolinesulphonyl)-2-methylpiperazine]. They also observed
that the L-type Ca2+ channel blocker verapamil could prevent IGF-1
and PDBU-stimulated sulphate—but not 3H-thymidine—incorporation,
which has led to the conclusion that PKC might regulate proliferation
via a calcium-independent mechanism. Furthermore, since the cAMP
analogue N6,O2-dibutyryl-adenosine-3′,5′-cyclic monophosphoric acid
had the opposite effects (i.e. it enhanced matrix synthesis but reduced
proliferation rate), the authors concluded that there is a close associa-
tion between the activities of PKC and PKA enzyme systems in the
mitogenic and metabolic processes of chondrocytes [36].
Although the results gained using phorbol esters and inhibitors
indirectly implicated PKC isoenzymes as positive regulators of chondro-
genesis, owing to lack of PKC subtype expression data, these early
observations were unable to deliver strong evidence concerning their
precise role. The initial ﬁndings describing the effects of these com-
pounds on chondrogenesis in vitro are summarised in Fig. 3.
4.3. Early studies to assess the role of PKCs during chondrogenesis
It was hypothesised that if the antichondrogenic effects of PMA on
embryonic limb bud-derived mesenchyme were mediated through
PKC overactivation and subsequent downregulation, inhibition of PKC
activity by a more speciﬁc inhibitor would have similar effects on carti-
lage formation. Staurosporine, an alkaloid derived from the bacterium
Streptomyces staurosporeus, is a prototypical ATP-competitive kinase
inhibitor which acts by preventing ATP from binding to the kinase;
therefore, it is an aspeciﬁc protein kinase inhibitor which preferentially
inhibits PKC with an IC50 value of 2.7 nM [37]. In 1991, however, Kulyk
observed opposing effects using staurosporine on micromass cultures
established from mesenchymal cells in embryonic chicken wing
bud-derived micromass cultures [38]. Quite intriguingly, he found that
treatments with staurosporine exerted chondro-stimulatory effects;
it not only brought about elevated cartilage matrix accumulationFig. 3. Effects of phorbol esters and select compounds on chondrogenesis, implicating involvem
andmimicked the chondrogenesis-promoting effects of the IGF-1 pathway, and this effect could
verapamil. Long-term exposure to PMAor TPA abrogated chondrogenesis; application of the com
the expression ofMsx1 that suppresses chondrogenic differentiation. These preliminary results i
were eitherhypothetic or could not be conﬁrmed at the timewhen these resultswere dissemina
growth factor-1; PMA, phorbol-12-myristate-13-acetate; TPA, 12-O-tetradecanoylphorbol-13-and enhanced cartilage-speciﬁc gene expression (cartilage-speciﬁc
proteoglycan and collagen type II) under high density culture condi-
tions (2 × 107 cells/mL) but it also induced extensive chondrocyte
differentiation even in low density cultures (2.5 × 106 cells/mL)
where cartilage formation does not spontaneously occur [38]. Further-
more, treatment with staurosporine was able to rescue the inhibitory
effect of PMA, which suggested that the observed effects might be
mediated through PKC. However, the chondrogenesis-promoting effect
of staurosporine on chondrogenesis could not be unequivocally attrib-
uted to PKC modulation in that study, owing to the promiscuity of the
inhibitor (see below). In fact, Kulyk hypothesised that in the developing
limb bud, the chondro-inhibitory effect of the ectodermal jacket on
chondroprogenitormesenchymal cells might bemediated via signalling
that involves phospholipase-mediated membrane phospholipid hydro-
lysis, DAG release, and resultant PKC activation. This theory is still yet to
be conﬁrmed.
By continuing this line of research, Kulyk and Reichert used HD
cultures ofmesenchymal cells from frontonasal, maxillary, andmandib-
ular processes, as well as hyoid arches of stage 24/25 chicken embryos
[39]. They found that staurosporine treatment enhanced chondrogene-
sis also in frontonasal and mandibular process mesenchyme, which
spontaneously developed numerous chondrogenic cell aggregates;
furthermore, it brought about extensive cartilage nodule formation in
maxillary process mesenchyme, which formed little cartilage matrix
under control conditions. Moreover, the presence of staurosporine initi-
ated chondrocyte differentiation in hyoid arch mesenchyme, which
demonstrated no spontaneous cartilage formation in control cultures
[39]. These results indicated that PKC might be a negative regulator of
chondrogenesis in chicken micromass cultures established from either
facial or limb primordia; alternatively, the observed effects could be
attributed to the highly aspeciﬁc nature of staurosporine as a protein
kinase inhibitor.
Apart from in vitro studies using primary cultures of mesenchymal
cells derived from embryonic limb buds or facial primordia, Ganan
and co-workers attempted to conﬁrm the role of PKC during digitent of PKC signalling. Short-term exposure to PDBU enhanced chondrogenic differentiation
be blocked by the PKC inhibitor compound H7 or the voltage gated Ca2+ channel blocker
petitive PKC inhibitor bryostatin I was able to compensate the effects of PMA. TPA altered
mplicated PKCs as positive regulators of chondrogenesis. Questionmarks indicate links that
ted. Please see text for details and references. (ECM, extracellularmatrix; IGF-1, insulin-like
acetate; PDBU, 12,13-dibutyrate).
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that at late stages of limb development, when the early patterning con-
trol mechanism has already ceased, the chick limb budwas able to form
fully differentiated extra digits by removing the ectoderm over the
interdigital spaces. They observed that microinjection of staurosporine
resulted in the formation of fully differentiated extra digits, which
appeared to be due to the induction of chondrogenesis following the
inhibition of PKC. However, as mentioned before, all the above effects
could also be attributed to the aspeciﬁc and promiscuous nature of
staurosporine.
To resolve the apparent contradiction between results gained using
either PMA or staurosporine, further attempts were made. By examin-
ing the temporal pattern of Sox9 expression in chicken embryonic
wing bud-derived HDC, Kulyk and co-workers found that staurosporine
rapidly upregulated Sox9mRNA, in advance of Col2a1 transcript expres-
sion, which suggests that staurosporine affects chondrogenic differenti-
ation by either directly or indirectly upregulating Sox9 upstream of
Col2a1 [41]. Quite interestingly, they also found that PMA treatments
caused a strong inhibition in Col2a1 transcript levels, without seriously
affecting Sox9 mRNA expression, an observation suggesting that
phorbol ester treatment inhibited Col2a1 expression by a mechanism
other than transcriptional control by Sox9. The authors suggested that
by downregulating PKC, phorbol esters could have altered the phos-
phorylation state and activity of the Sox9 transcription factor, thus caus-
ing Col2a1 downregulation.
To conclude, these preliminary observations using staurosporine as
a compound to inhibit PKC are contradictory to what the previous set
of experiments using phorbol esters suggested. However, as discussed
later, these initial studies using compounds that are highly aspeciﬁcFig. 4.Effects of staurosporine, anATP-antagonist protein kinase inhibitor, on chondrogenesis. T
Col2a1mRNA expressions, and prevented the chondro-inhibitory effect of PMA. Furthermore,
effectswere later proved to bePKC-independent. Questionmarks indicate links thatwere either
details and references, please see text. (ECM, extracellular matrix).could have led to inappropriate conclusions. Fig. 4 summarises the
ﬁrst results gained using staurosporine on chondrogenesis.
4.4. PKC isoform expression and activity during chondrogenesis
The previously mentioned studies either applied phorbol esters to
activate and/or downregulate, or inhibitors such as staurosporine to
block PKC activity; the authors of these papers made their conclusions
solely by relying on the indirect pieces of evidence deduced from the
effects of these compounds, without providing direct proof for the
presence of PKC isoenzymes either at mRNA or protein levels, nor did
they perform de facto PKC enzyme activity assays. It was not until
1993 that the latter ﬂaw has been addressed by Sonn and Solursh,
who assayed PKC activity for the ﬁrst time in both cytosolic and partic-
ulate fractions of HD cultures established from stage 23/24 chick limb
bud chondroprogenitor cells [42]. Initially, PKC activity was low, but
during the course of chondrogenesis, cytosolic PKC activity signiﬁcantly
increased, while that of the particulate fraction increased only slightly.
One of the most straightforward arguments of the determining role of
PKC in the regulation of chondrogenesis was that PKC activity in
cultures seeded at low density (5 × 106 cells/mL) where chondrogene-
sis is reduced was as low as that in 1-day-old cultures of cells plated at
high density (2 × 107 cells/mL), which favours chondrogenic differentia-
tion. These enzyme activity measurements unequivocally demonstrated
that PMA inhibited chondrogenesis by depressing PKC; moreover, they
also found that in the embryonic limb bud-derived system, staurosporine
promoted chondrogenesis without affecting PKC activity—in contrast to
earlier ﬁndings inmicromass cultures established from embryonic chick-
en facial or wing primordia [38,39]. Thus, the fact that staurosporine actsreatmentwith staurosporine enhanced chondrogenic differentiation, upregulated Sox9 and
staurosporine induced extra digit formation in chicken embryos. However, most of these
hypothetic or could not be conﬁrmed at the timewhendatawere disseminated. For further
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has been unequivocally conﬁrmed.
Once de facto PKC enzyme activity measurements in chondrifying
micromass cultures have been disseminated [42], the quest for identify-
ing PKC isoenzymes expressed in cartilage at various stages of develop-
ment has started. By using a pan-PKC antiserum recognising the
catalytic domain of the enzyme, Bareggi and co-workers were the ﬁrst
to report that PKC was markedly expressed in chondrocytes in foetal
mouse thoracic vertebrae [43]. In particular, chondrocytes were found
to heavily express PKCβ, but they were also weakly stained by the
anti-PKCε antiserum. Based on the immunohistochemical staining reac-
tions, the authors concluded that PKCβmight play an important role in
cartilage formation of the mouse axial skeleton. They then continued
their experiments and performed an immunohistochemical analysis on
the vertebral column of human embryos by using polyclonal antibodies
to study the presence and distribution of nine PKC isoenzymes [44].
They investigated a key developmental period (developmental week
8), when the majority of chondrogenic differentiation processes occur
during human embryonic development. Based on their results, the
authors speculated that the appearance, localisation and activation of
various PKC isoforms in chondrocytes might depend on the actual
stage of chondrogenesis and that these enzymes may be key regulators
of the process.
Shortly after these initial studies, Choi and co-workers examined the
expression pattern of PKC isoenzymes in micromass cultures derived
from the distal limb buds of chicken embryos with isoenzyme-speciﬁc
anti-PKC antibodies, which gave a head start for further research in
this ﬁeld [45]. This group was the ﬁrst to demonstrate that PKCα and
PKCγ (but not PKCβ) of the conventional PKCs; PKCε (but not PKCδ) of
the novel PKCs; as well as PKCλ/ι and PKCζ of the atypical PKCs were
expressed throughout the 5-day-long culturing period. It is of note
that theywere unable to identify PKCβ in that system, and in this respect
their data contradict to those of Bareggi and co-workers who reported
that PKCβwas the PKC subtype with the strongest expression in devel-
oping mouse vertebrae [43]. Furthermore, since chondrogenesis was
completely abrogated by applying speciﬁc PKC inhibitors such as
bisindolylmaleimide or calphosptin, they conﬁrmed earlier results
concerning the determining role of PKCs in the regulation of cartilage
formation. They could also make clear distinction between the involve-
ment of different PKC subtypes; as chronic exposure to PMA consider-
ably lowered the protein expression of cPKC and nPKC (but not aPKC)
isoenzymes, they concluded that these subtypes were required for
chondrogenesis to properly occur. By downregulating the expression
of these PKCswith PMA at various stages of differentiation, the strongest
inhibition of chondrogenesis was detected when PMA was applied for
the ﬁrst 24 h; furthermore, loss of PKC activity exerted a negative effect
on both proliferation and cartilage ECM synthesis. These data indicate
that PKCs are important regulators of the early stages of chondrogenesis.
In another report, Yang and co-workers established that among the
PKC isoforms expressed in chicken limb bud-derived HDC at the protein
level, expressions of PKCα and PKCε in the particulate membrane
fraction were increased during in vitro chondrogenic differentiation,
suggesting a determining role of these isoenzymes [46]. In support of
this theory, by selectively blocking or downregulating PKCα, chondro-
genesis could be inhibited; furthermore, there was a close correlation
between the degree of chondrogenesis and the expression levels of
PKCα, but not other PKC isoforms, which indicates that PKCα is a quin-
tessential regulator of chondrogenesis [46]. Taken together, by compar-
ing data derived from enzyme activity assays which suggested that PKC
activitywas initially low and then gradually increased as chondrogenesis
progressed [42]with data fromprotein expression patterns showing that
levels of PKCα, PKCγ and PKCε were initially low and then gradually
increased with chondrogenesis, there is a perfect correlation between
the two independent approaches.
In summary, the above results indicate that the expression and acti-
vation of PKCα act as an important induction signal for chondrogenicdifferentiation of mesenchymal cells under micromass conditions:
PKCα expression was low in undifferentiated progenitor cells but
dramatically increased before chondrogenesis commenced in both
cytosolic and particulatemembrane fractions. Themost important argu-
ment in supporting the central role of PKCα is that its inhibitionwas suf-
ﬁcient to block chondrocyte differentiation.
In a good correlation with the results of Choi and co-workers, Grill
and colleagues veriﬁed the expressions of three PKC isoenzymes
(PKCα, PKCε and PKCζ) in primary chondrocytes isolated from the
tibiae of 6-day old chicken embryos [47]. In cells cultured for 20 days
(i.e. they retained their chondrocyte phenotype) PKCε was the most
prominently expressed isoform, whereas PKCα exhibited the least
intense signals. To the contrary, once cells have undergone further
differentiation towards the osteoblastic phenotype, PKCα was the
most prominently expressed isoform, and a marked decrease of PKCε
expression was detected. In terms of PKCζ expression no apparent
differences have been detected between the two stages studied. Based
on these ﬁndings, the authors concluded that these PKC isoenzymes
may play roles at different levels of chondrocyte differentiation (i.e.
mature vs. hypertrophic chondrocytes).
The same research team performed further immunocytochemical
analyses on the expression of various PKC isoenzymes (i.e. PKCα, PKCδ,
PKCε and PKCζ) in primary adherent cultures of chick chondrocytes
derived from 6-day-old tibiae. They demonstrated that PKCζ exhibited
a much stronger immunopositivity as compared to PKCα; furthermore,
PKCδ and PKCεwere even less expressed at the cell culture stage inves-
tigated [48]. Based on signal strength, the authors suggested that a
major role could be played by PKCα and PKCζ in this particular phase
of chondrogenesis. In another study when they monitored the expres-
sions of PKC isoenzymes at various differentiation times (i.e. 48, 55, 62
and 69 days after cell collection from the tibiae of 6-day-old chick embry-
os), they reported that PKCζ was the isoenzyme that exhibited the
strongest immunocytochemical expression in chondrocyte cultures at
all ages, whereas PKCε has always proved to be theweakest as compared
to the other PKC isoforms. As opposed to PKCε and PKCζ, no obvious
differences in the expression patterns of PKCα and PKCδ could be
observed at any time point [49]. The authors thus concluded that all
PKC isoenzymes studied (i.e. PKCα, PKCδ, PKCε and PKCζ) may play
peculiar roles in the differentiation process of chicken tibia-derived
chondrocytes towards the osteoblastic phenotype.
In whole cell lysates of cultured primary human articular
chondrocytes and C-20/A4 cells, Lee and colleagues investigated the
expression of PKC isoenzymes using Western blotting and revealed
that primary chondrocytes expressed PKC subtypes α, γ, δ, ι and λ,
whereas PKCα, ι, λ and εwere identiﬁed in C-20/A4 cells [50]. Further-
more, they also described a role of PKCα in mediating chondrocyte
mechanotransduction; following mechanical stimulation at 0.33 Hz,
chondrocytes exhibited a rapid, integrin-dependent translocation of
PKCα to the cell membrane, implicating an important role for PKC and
integrin-mediated signalling.
LaVallie and colleagues also demonstrated the presence of multiple
PKC subtypes in human chondrocytes [51]. However, in contrast to
the previous investigators in this ﬁeld, they used a different approach;
they applied Affymetrix GeneChip® arrays to speciﬁcally identify
mRNA transcripts of PKC family members. Probe sets for nine PKC
isoforms were represented on the array as follows: α, β, γ, δ, ε, θ, η, ι,
and ζ; of these, only four PKC isoforms, i.e. PKCδ, PKCι, PKCθ, and PKCζ
were judged to be present in human mature chondrocytes by virtue of
their hybridisation intensity levels. Moreover, of these four PKC
isoforms, only PKCδ and PKCζ exceeded an empirically determined
signal intensity threshold allowing reliable quantitation of their tran-
script levels on the gene chips [51]. The fact that PKCαmRNA transcript
levels were not considered to be heavily expressed could stem from the
different experimental setups applied in that study. In agreement with
these data, our laboratorywas the ﬁrst to show PKCδmRNA and protein
expression during in vitro chondrogenesis in chicken embryonic limb
Table 1
Chronological order of publications describing PKC isoenzyme expression and function during chondrogenesis and/or in chondrocytes derived from various model systems using various
experimental approaches.
Organism and model system PKC isoenzyme(s) Comment Reference
1. HDC from the distal limb
buds of chicken embryos
Overall PKC activity Measured PKC activity in cytosolic and particulate fractions for the ﬁrst time. PMA inhibited
chondrogenesis by reducing PKC activity; staurosporine had PKC-independent effects
[42]
2. Foetal mouse thoracic
vertebrae
PKCβ, PKCε Implication of PKCβ as main isoform during cartilage formation of the mouse axial
skeleton by immunohistochemical approach
[43]
3. Vertebral column of human
embryos
Various PKC isoforms Stage-dependent appearance of various PKC isoforms during cartilage formation by
immunohistochemical approach
[44]
4. HDC from the distal limb
buds of chicken embryos
cPKC: PKCα, PKCγ; nPKC: PKCε;
aPKC: PKCλ/ι, PKCζ
Conﬁrmed expression of speciﬁc PKC isoforms using immunoblots. Inhibitors
(bisindolylmaleimide or calphosptin) abrogated chondrogenesis. Conﬁrmed that
PMA downregulates PKC.
[45]
5. HDC from the distal limb
buds of chicken embryos
PKCα, PKCε Increased expression of PKCα and PKCε in the particulate membrane fraction during
chondrogenesis; by selectively blocking PKCα, chondrogenesis was inhibited; close
correlation between the degree of chondrogenesis and PKCα expression levels—PKCα
is a quintessential regulator of chondrogenesis
[46]
6. Chondrocytes isolated from
the tibiae of 6-day old
chicken embryos
PKCα, PKCε, PKCζ PKCε prominently expressed and PKCα showed less intense signals in chondrocytes;
opposite pattern in osteoblastic cells; no difference in PKCζ expression
[47]
7. Chondrocytes isolated from
the tibiae of 6-day old
chicken embryos
PKCα, PKCδ, PKCε, PKCζ PKCζ exhibited amuch stronger immunopositivity than PKCα; PKCδ and PKCεwere even less
expressed. PKCα and PKCζ are key regulators
[48]
8. Primary cultured human
articular chondrocytes and
C-20/A4 cells
PKCα, PKCγ, PKCδ, PKCι and PKCλ in
primary cells; PKCα, PKCι, PKCλ and
PKCε in C-20/A4
Western blotting revealed that primary chondrocytes expressed PKC subtypesα,γ, δ, ι andλ,
whereas only PKCα, ι, λ and εwere identiﬁed in C-20/A4 cells. Role of
PKCα in mechanotransduction pathways.
[50]
9. Chondrocytes isolated from
the tibiae of 6-day old chicken
embryos; time series
PKCα, PKCδ, PKCε, PKCζ PKCζ exhibited strongest immunocytochemical expression at all time points; PKCεwas
always the weakest
[49]
10. Mature human chondrocytes PKCδ, PKCι, PKCθ, PKCζ Affymetrix GeneChip® array analysis; only PKCδ and PKCζ exhibited strong expression levels [51]
11. HDC from the distal limb buds
of chicken embryos
PKCδ PKCδmRNA and protein expressions; PKCδ has chondrogenesis-promoting effects [52]
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tive regulator of chondrogenic differentiation of mesenchymal cells
[52]. Various PKC isoenzymes described during chondrogenesis and/or
in mature chondrocytes by different laboratories are shown in Table 1.
Once the presence and central role of many PKC isoenzymes has
been conﬁrmed at bothmRNA and protein levels, aswell as PKC activity
has also been detected during chondrogenesis, attempts to understand
their precise role in mediating signalling processes to drive in vitro
chondrogenesis have been initiated. In the following section of this re-
view article, we are providing an overview of what processes and sig-
nalling pathways are implicated to be involved in PKC signalling
during chondrogenesis.
5. PKCs regulate the chondrocyte phenotype via the
actin cytoskeleton
The actin cytoskeleton serves numerous vital functions in any cell
type. Besides providing cells with structural and mechanical stability,
it also serves as a major organiser for signalling pathways that regulate
adhesion and intercellular communication. The cytoskeletal architec-
ture can undergo rapid changes in conformation and arrangement in
response to extracellular stimuli, which can lead tometabolic activation,
differentiation, proliferation, or apoptosis. Healthy chondrocytes are
characterised by a faint microﬁbrillary actin cytoskeleton; in contrast,
dedifferentiating chondrocytes with ﬁbroblastic morphology lack this
well organised network and possess thick actin cables (stress ﬁbres)
along with altered ECM and collagen synthesis [53]. A possible role for
the actin cytoskeleton in chondrocyte differentiation was suggested by
the initial observations on the ability of spherical chondrocytes cultured
in agarose gels to maintain chondrogenic phenotype and conversely, to
lose it when cultured in monolayers [54,55].
Staurosporine as well as other PKC inhibitors such as PMA or com-
poundH7have longbeen shown to rapidly disorganise themicroﬁlament
cytoskeletal network and consequently induce changes in cell shape and
adhesion [56]. Given that a transition from a ﬁbroblastic shape to a round
chondrocyte-like phenotype, through actin reorganisation, is a prerequi-
site to chondrogenesis [57], Borge and co-workers tested the hypothesiswhether reorganisation of the actin cytoskeleton restored the differenti-
ated phenotype of serially passaged undifferentiated chondrocytes [58].
They found that treatment with staurosporine restored the synthesis of
collagen type II and sulphated ECM components and at the same time
suppressed collagen type I and III production. The authors concluded
that the capacity of staurosporin to reinduce the expression of the differ-
entiated phenotype in chondrocytes could primarily be attributed to the
reorganisation of the actin microﬁlaments, rather than a consequence of
PKC inhibition. In another study by Hoben and colleagues staurosporine
was applied as an actin-modifying agent to increase the gene expression
and synthesis of major ﬁbrocartilage ECM components in a monolayer
culture of ﬁbrochondrocytes and established that staurosporine could
be used to enhance matrix production and reduce contraction in tissue-
engineered ﬁbrocartilage constructs, without implicating the involve-
ment of PKC subtypes [59].
Nevertheless, Lim and co-workers provided direct evidence that dis-
ruption of the actin cytoskeleton by cytochalasin D enhances in vitro
chondrogenesis by activating PKCα and by inhibiting the ERK-1 signalling
pathway [60]. Using embryonic chicken wing bud-derivedmesenchymal
cells cultured in subconﬂuent clonal cell density (6 × 105 cells/mL), both
cytochalasin D and latrunculin B induced chondrogenesis via increased
expression and activation of PKCα. In accordancewith the aboveﬁndings,
extensive stressﬁbre networkwas observed in chondrogenic cells seeded
at this low density, which is non-permissive for chondrogenesis to take
place. However, disorganisation of the actin cytoskeleton by cytochalasin
D failed to initiate chondrogenesis when PKCα was concurrently
inhibited with Gö6976, a rather speciﬁc inhibitor of PKCα, or depleted
by chronic exposure to PMA. Since the expression levels of other PKC
isoforms such as PKCε and PKCλ/ι did not signiﬁcantly change in the
presence of cytochalasin D, these data clearly indicated that signalling
through PKCα was essential for chondrogenic differentiation of limb
bud-derived mesenchymal cells at clonal cell densities.
The link between actin cytoskeleton and PKC signalling in
chondrocytes has been further studied by Kim and co-workers. It has
long been known that exposure to nitric oxide (NO) initiates dediffer-
entiation and/or apoptosis in mature chondrocytes via signalling that
involves the MAPK cascade and by inhibiting PKCα and PKCζ [61]. By
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existing actin ﬁlaments, or induce actin polymerisation and stabilise
actin in a polymeric form, Kim and colleagues could unequivocally
prove that the actin cytoskeletal architecture is a critical regulator of
articular chondrocyte function [62]. They found that disruption of the
actin cytoskeleton structure prevents NO-induced dedifferentiation by
eliminating the NO-evoked inhibition of PKCα and PKCζ.
In 2007, Nurminsky and co-workers supplied further evidence on
the interdependence of cytoskeletal organisation and chondrogenic
gene expression [63]. They found that the expression of the gelsolin-
like actin-binding protein adseverin (also known as scinderin) is
dramatically upregulated during chondrocyte maturation in a PKC
dependent manner in chicken chondrocytes. Treatments with PKC
inhibitor bisindolylmaleimide I (GF109203X) caused dedifferentiation
of chondrocytes: cells acquired ﬁbroblastic morphology along with
complete abrogation of Ihh and collagen type X expression. Adseverin
expression was similarly reduced in bisindolylmaleimide-treated
chondrocytes, which implicated that adseverin upregulation is speciﬁ-
cally linked to the chondrocytematuration programme and is regulated
by the PKC pathway [63]. Although the latter study was performed on
terminally differentiating chondrocytes, it is plausible that the same or
at least similar molecular mechanism may control changes in cell
shape during primary chondrocyte differentiation.
The recently published paper by Rottmar and his group also came to
the same conclusions: both staurosporine and cytochalasin D augment-
ed chondrogenic gene expression in dedifferentiated ﬁbroblastic bovine
articular chondrocytes, and the PKC pathwaywas a positive regulator of
this phenomenon [64].
Based on the above ﬁndings, the following model for PKC-induced
actin cytoskeleton reorganisation can be proposed (Fig. 5). DuringFig. 5. Proposed model for PKC-induced actin cytoskeleton reorganisation during chondroge
cytochalasinD, lantriculin B) enhancePKC activity and at the same time inhibit ERK1/2; both pat
(i.e. upregulate Col2a1, and downregulate Col1a1 and Col3a1). Nitric oxide (NO)-induced dedi
indispensable to chondrogenesis induces changes in the expression patterns of various factors in
changes in cell shape from a ﬁbroblastoid to a rounded chondrocyte-like phenotype. Various P
level, a putative link between PKC and ERK1/2 signalling has not been established. Please see t
experimental model applied in these initial studies, activation of ERK1/2 negatively regulates cchondrogenesis, PKC activity increases, which induces changes in the
expression patterns of various factors including adseverin that causes
reorganisation of the actin cytoskeleton, thereby promoting changes in
cell shape from a ﬁbroblastic to a rounded chondrocyte-like phenotype.
6. PKC exerts its chondrogenesis-promoting effect via the
ERK–MAPK pathway
Although PKCs have long been known to positively regulate in vitro
chondrogenesis, the mechanisms through which they exert their
functions are yet to be clariﬁed. Since MAP-kinases are central regula-
tors of chondrogenic differentiation [65], it is not surprising that
among other signalling systems, PKCs are also upstream modulators of
this pathway. According to what has been described earlier, the MAPK
family comprises three major cytoplasmic cascades: ERK1/2, p38, and
JNK pathways. Given the prominent role of the ERK1/2 pathway in the
regulation of chondrogenesis, it is quite evident that the majority of
research aiming at establishing a link between PKC andMAPK signalling
has been carried out with the ERK1/2 pathway in focus.
6.1. PKC mediates chondrogenesis via the ERK1/2 pathway
The ﬁrst link between PKC and ERK1/2 pathways has been
established by Scherle and co-workers in 1997. They found that a
20-min-long treatment with the potent PKC activator PDBU evoked
a more than 10-fold stimulation of ERK1/2 activity in isolated rabbit
articular chondrocytes, without affecting p38 and JNK activities
[66]. In 1998, Chang and co-workers have conﬁrmed these results,
demonstrating that PKC regulates chondrogenesis by modulating
N-cadherin expression via ERK-1 activity in chicken wing bud-derivednesis. Compounds that induce reorganisation of the actin cytoskeleton (staurosporine,
hways promote chondrogenic differentiation and induce cartilage-speciﬁc geneexpression
fferentiation of the chondrocyte phenotype is also blocked. Enhanced PKC activity that is
cluding adseverin that causes reorganisation of the actin cytoskeleton, thereby promoting
KC inhibitors (PMA, Gö6976, GF109203X) exert negative effects on this pathway. At this
ext for further explanation and references. Note that in the chicken limb bud-derived HD
hondrogenesis.
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arguments:
(1) Inhibition of PKC enzyme activity resulted in the activation of
ERK-1, and at the same time chondrogenesis was blocked.
(2) Inhibition of ERK-1 with PD98059 (2-[amino-3-methoxyphenyl]-
4H-1-benzopyran-4-one) augmented chondrogenesis; further-
more, it was able to rescue decreased rate of chondrogenesis
brought about by blockade of PKC activity.
(3) ERK-1 inhibition did not affect expression and subcellular distri-
bution of PKC isoforms in micromass cultures.
(4) Inhibition of PKC activity modulated the expression of cell adhe-
sionmolecules (N-cadherin, integrin) involved in precartilaginous
condensation, which was reversed by the inhibition of ERK-1.
From these data, the authors concluded that ERK-1 modulates
synthesis and/or activation of transcription factors that regulate the
expression of cell adhesion molecules and ECM components via signal-
ling that involves PKC.
The fact that PKC is acting upstream of ERK1/2 was reinforced by Oh
and colleagues in 2000. They conﬁrmed that the amounts and expression
patterns as well as the distribution of PKC isoforms expressed in
chondrifying micromass cultures between cytosolic and particulate
membrane fractionswere essentially the same in the absence orpresence
of the p38 inhibitor SB203580 (4-[4-ﬂuorophenyl]-2-[4-pyridyl]-1H-
imidazole) or the ERK1/2 inhibitor PD98059; conversely, inhibition of
PKC with the PKCα and PKCβ-speciﬁc inhibitor Gö6976, or down-
regulation of PKC with prolonged exposure of cells to PMA resulted
in an increased level of P-ERK-1 and consequent inhibition of chon-
drogenesis. Moreover, in untreated control cultures, the decrease in
ERK1/2 activities that favours chondrogenesis was highly correlat-
ed with the increased expression and activation of PKCα and PKCε
isoforms [8].
As an attempt to identify an upstream activator of PKCα in differen-
tiating chondroprogenitors, the molecular mechanism of the glucose
effect on the regulation of chondrogenesis has been studied in detail
by Han and colleagues. They observed that exposure of micromass
cultures derived from chick wing bud mesenchymal cells to high
concentrations of glucose (30 mM or higher) signiﬁcantly stimulated
chondrogenesis without affecting cell proliferation. Furthermore, their
results implied that the observed effects could be attributed to PKCα;
its levels and the membrane translocation were increased by glucose
treatment, leading to a reduction of P-ERK1/2 levels, and at the same
time enhancing p38 phosphorylation. Apart from changes in phosphor-
ylation status of key signalling targets, glucose also modulated the
expression patterns of cell adhesion molecules including ﬁbronectin,
integrin β1, and N-cadherin. The key argument in favour of their
hypothesis was that these alterations in protein level of adhesion
molecules and in the phosphorylation status ofMAPKs could be blocked
by inhibition of PKC using GF109203X, which has led to the conclusion
that high doses of glucose induce the downregulation of ERK1/2 activity
in a PKCα dependent manner and stimulate in vitro chondrogenesis via
modulating the expression of key adhesion molecules [68].
The results of our laboratory suggest that the novel PKC isoform
PKCδ also regulates chondrogenesis, at least partially, via the ERK1/2
pathway [52]. In this study, either the natural compound rottlerin was
applied or transient gene silencing was performed using PKCdelta
shRNA to inhibit PKCδ activity. Both rottlerin and PKCδ shRNA caused
a severe reduction in cartilage formation, furthermore protein and
phospho-protein levels of Sox9, the key transcription factor of chondro-
genesis, were also signiﬁcantly decreased. However, rottlerin lowered,
while PKCδ gene silencing elevated the phosphorylation status of
ERK1/2. Our data suggested that PKCδ stimulated chondrogenesis via
inﬂuencing Sox9 and ERK1/2 phosphorylation, but the inhibition of
cartilage formation in the rottlerin-treated HDC was probably partially
PKCδ independent.6.1.1. PKC–ERK1/2 signalling through the actin cytoskeleton
There are many other processes during chondrogenesis and/or in
mature chondrocytes in which PKC-mediated MAPK signalling plays a
central role. As mentioned earlier, disruption of the actin cytoskeleton
by cytochalasin D induced chondrogenesis of mesenchymal cells even
at low cellular densities via a PKCα dependent mechanism [60]. At the
same time, treatment with cytochalasin D reduced ERK-1 phosphoryla-
tion, which is consistent with other observations suggesting that ERK
activation is regulated by reorganisation of the actin cytoskeleton [69].
Since ERK-1 is a negative regulator of chondrogenesis in chick limb
bud-derived mesenchymal cells [67], the authors assumed that the
decrease in P-ERK-1 levels could at least partially be accounted for
enhanced chondrogenesis. However, application of the ERK-1 inhibitor
PD98059 failed to further enhance the induced chondrogenesis, which
suggested that the ERK-1 pathway alone was insufﬁcient for inducing
chondrogenesis and other pathways were also involved.
As it was discussed earlier, Nurminsky and co-workers found a close
interdependence of actin cytoskeletal organisation and chondrogenic
gene expression in a PKC-dependentmanner during terminal differentia-
tion of hypertrophic chicken chondrocytes [63]. Moreover, since applica-
tion of theMEK-inhibitor U0126 also resulted in similar inhibitory effects,
involvement of the MEK–ERK1/2 pathway was also implicated. Thus,
they concluded that activation of PKC signalling in non-hypertrophic
chondrocytes induces adseverin expression in aMEK-dependentmanner
(see Fig. 5). Similar ﬁndings were reported also by Rottmar and
colleagues who found that the p38-MAPK pathway positively regulated
chondrogenesis, while the ERK-pathway was a negative regulator in
staurosporine-induced re-differentiation [64].
Based on the results summarised in this section, the proposedmech-
anism of PKC-dependent regulation of chondrogenesis via the ERK1/2
MAPK pathway and modulation of cell adhesion molecules is shown
in Fig. 6.
6.2. PKC, p38 MAPK and chondrogenesis
The increased expression and activity of PKC are required for down-
regulation of ERK-1, a negative regulator of in vitro chondrogenesis,
which correlates well with the induction of chondrogenic differentia-
tion of embryonic chondroprogenitor cells. In contrast to ERK-1, p38
activity is increased during chondrogenesis, and inhibition of p38 MAP
kinase blocks chondrogenesis [8]. As mentioned above, Oh and co-
workers provided important data that ERK1/2 is a downstream target
of PKC signalling in chick limb bud-derived chondrifying micromass
cultures; however, they also found that neither inhibition of classic
PKC isoenzymes with Gö6976 nor downregulation with prolonged
exposure to PMA affected p38 activity in these cultures. These results
indicated that unlike ERK1/2, p38 was not linked to the PKC signalling
pathway [8].
Later on, the same research group observed that the chondrogenesis-
inhibitory effects of the immunosuppressant rapamycin were mediated
via inhibition of PKCα activation (but not the expression) during nodule
formation, without altering the phosphorylation status of ERK-1 [70]. In
contrast, p38 kinase activity was found to be dramatically reducedwhen
cells were exposed to rapamycin, with concurrent inhibition of chondro-
genesis. However, as the inhibition or downregulation of PKCα did not
affect p38 activity, the rapamycin-mediated regulation of PKCα signal-
ling appeared to be independent of p38 MAP kinase signalling.
To further dissect themolecular mechanism of PKC-mediatedMAPK
signalling during chondrogenesis and to search for possible upstream
regulators, Jin and co-workers studied the possible interrelation be-
tween TGF-β3 andWnt-5a, two important modulators of chondrogenic
differentiation of mesenchymal cells. They demonstrated that TGF-β3
stimulates in vitro chondrogenesis by upregulating Wnt-5a expression.
Furthermore, the downstream targets of this pathway include PKCα
and p38 as overexpression of Wnt-5a or treatment with exogenous
TGF-β3 stimulated the activation of these two kinases, whereas
Fig. 6.Model to explain the role of PKC (primarily PKCα, PKCδ and PKCε) in mediating the effects of high extracellular glucose (≥30 mM) and reorganisation of the actin cytoskeleton.
Based on the initial results, the hypothesis is that ERK1/2 modulates the expression of cell adhesionmolecules (i.e. integrin, N-cadherin) and ECM components via signalling that involves
PKC. For further details and references please see text. Note that in the chicken HDC applied in these studies, ERK1/2 is a negative regulator of chondrogenesis. (CAM, cell adhesion mol-
ecule; ECM, extracellular matrix; SB203580, p38 MAPK inhibitor; PD98059, ERK1/2 MAPK inhibitor).
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by depletion of cytosolic Ca2+ with EGTA; or PD169316, respectively)
completely abrogated chondrogenesis stimulated by both TGF-β3 and
Wnt-5a. These results implicated that Wnt-5a mediates the chondro-
stimulatory effect of TGF-β3 through upregulation of PKCα and p38
signalling [71].
6.2.1. PKC–p38 signalling through the actin cytoskeleton
As discussed earlier, Lim and co-workers have shown that disruption
of the actin cytoskeletonwith cytochalasin D in subconﬂuent chick limb
bud-derived chondroprogenitor cells induced chondrogenic differentia-
tion, mediated through increased expression and activity of PKCα [60].
Since it has long been known that disassembly of actin ﬁlaments has al-
tered the phosphorylation status of both ERK1/2 and p38 [72], Lim and
co-workers undertook to investigate the possible role of ERK1/2 and
p38 in PKCα-regulated chondrogenesis of subconﬂuent mesenchymal
cells induced by cytoskeleton disruption. They demonstrated that acti-
vation of p38 was necessary for cytochalasin D-induced chondrogene-
sis. Furthermore, inhibition or downregulation of PKC by the potent
and selective PKC inhibitor GF109203X (bisindolylmaleimide I) or
PMA, respectively, blocked cytochalasin D-induced p38 activation,
whereas inhibition of p38 with SB203580 did not alter the expression
and activity of PKC. These results imply that a PKC–p38MAP kinase path-
way regulates the induction of chondrogenesis by disruption of the cyto-
skeleton [73], which is an important difference compared to micromass
culture-induced chondrogenesiswhen p38 is independent of PKC signal-
ling [8]. Similar conclusions were drawn also from the observations of
Rottmar and colleagues [64]. Fig. 7 shows a schematic pathway of the in-
volvement of PKC and p38 MAPK signalling during chondrogenesis.
6.3. Chondrocyte de- and redifferentiation are regulated by PKC and MAPK
signalling
Once the signalling mechanisms involving the PKCα-dependent
ERK-1 pathway that governs chondrocyte differentiation have beenclearly elucidated, Yoon and colleagues undertook to decipher the
functions of this signalling in maintaining the chondrocyte phenotype
[74]. They used serially passaged monolayer cultures of chondrocytes
derived from rabbit articular cartilage and studied their de- and
redifferentiation in three-dimensional cultures. The fact that PKCα
was required for themaintenance of differentiated chondrocyte pheno-
type was conﬁrmed by the observation that its downregulation by
prolonged treatment with PMA caused dedifferentiation. Interestingly,
since treatment of chondrocytes with the PKC inhibitors GF109203X
or Gö6976 did not cause dedifferentiation, the authors speculated that
it is the expression, rather than the activity, of PKCα that was required
for the maintenance of differentiated chondrocyte phenotype. At the
same time, they also demonstrated that PKC and ERK1/2 independently
regulated dedifferentiation of chondrocytes since PKCα overexpression
did not block enhanced ERK phosphorylation required for the recovery
of chondrocyte phenotype. In conclusion, these and earlier data suggest
that chondrocyte differentiation in micromass cultures is mediated by
PKC-dependent ERK1/2 regulation, while PKCα and ERK1/2 separately
control chondrocyte dedifferentiation [74].
The relationship between PKC signalling and p38 MAPK has been
further analysed by Lee and colleagues in 2007 who investigated
the effects of chitosan on the redifferentiation of dedifferentiated
chondrocytes obtained from a micromass culture system of chick wing
bud mesenchymal cells. Mature chondrocytes were subjected to serial
monolayer subculturing which yielded dedifferentiated cells. When
the dedifferentiated chondrocytes were cultured on chitosan mem-
branes they regained the phenotype of differentiated chondrocytes.
They also observed that expression of PKC increased during chondro-
genesis, decreased during dedifferentiation, and increased again during
redifferentiation, implicating an important regulatory role of this
pathway. This was further supported by the fact that PMA-treatment
of dedifferentiated chondrocytes inhibited redifferentiation and down-
regulated PKC. In addition, the expression of p38 MAPK increased
during redifferentiation and its inhibition suppressed redifferentiation.
If we consider the fact that chondrocyte de- and redifferentiation also
Fig. 7. PKC signalling is involved in activating the p38MAPK pathway to enhance chondrogenesis. TGF-β3 stimulates chondrogenic differentiation through upregulation ofWnt5-a, which
in turn activates the PKCα–p38 pathway. Disruption of the actin cytoskeleton by cytochalasin D can also activate the p38 MAPK pathway in a PKCα dependent manner. Note that the
PKC–p38 MAPK pathway is reported to regulate the induction of chondrogenesis by disruption of the cytoskeleton, unlike micromass culture-induced chondrogenesis when p38 is
independent of PKC signalling. Similarly, rapamycin suppressed chondrogenesis via a p38 independent mechanism. For more detailed explanation and relevant references, please see
text. (SB203580 and PD169316, p38 MAPK inhibitors).
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reorganisation of the actin cytoskeleton, these ﬁndings indicate that
PKC and p38 activities, along with cytoskeletal reorganisation, are
essential for chondrocyte redifferentiation [75]. Fig. 8 depicts the
PKC-dependent regulation of chondrocyte differentiation, dedifferenti-
ation and redifferentiation processes.
6.4. PKC mediates the effects of IGF-1 and EGF during chondrogenesis
IGF-1 is known to be expressed in developing cartilage within the
condensing region of the embryonic limb bud as well as in mature
cartilage and synovial ﬂuid, where it regulates chondrogenesis and
anabolism of cartilage ECM molecules. As described above, Taylor and
colleagues suggested an active regulatory role for PKCs in mediating
IGF-1 induced metabolic and mitogenic effects in isolated articular
chondrocytes [36] (see Fig. 3). However, at that time, they did not aim
to provide a detailed analysis of the signalling pathways involved in
mediating the effects of IGF-1. Several years later Oh and Chun
published a paper on the signallingmechanisms leading to IGF-1 action[76]. According to their results, IGF-1 induces chondrogenic differentia-
tion of chick limb bud-derived mesenchymal cells by activating PI-3K,
which in turn leads to the subsequent activation of PKCα and p38, and
at the same time inhibition of ERK1/2. Their results indicated that
although the expression and activation of PKCα were required for
chondrogenesis to take place, ectopic expression of PKCα alone was
insufﬁcient to activate p38 and subsequently to induce chondrogenesis
in the absence of IGF-1 or serum.
During embryonic limb development, epithelial cells in the apical
ectodermal ridge (AER) keep the underlying mesenchymal cells in
state of mitotic proliferation, which prevents differentiation, by secret-
ing signalling molecules such as the epidermal growth factor (EGF).
When Yoon and co-workers scrutinised the molecular mechanism by
which EGF inhibits chondrogenesis they found that exogenous EGF
treatment inhibited the expression and activation of PKCα, and at the
same time activated ERK-1 and inhibited p38, all of which has led to
inhibition of chondrogenesis. Furthermore, stimulation of the EGF
receptor blocked precartilage condensation and altered the expression
of cell adhesion molecules such as N-cadherin and integrin α5β1; all
Fig. 8. Schematic diagram depicting the suggested role of PKCα, ERK1/2 and p38 MAPK in differentiation, dedifferentiation, and redifferentiation of chondrocytes. PKCα acts as a positive
regulator during differentiation of chondroprogenitor cells to chondrocytes and redifferentiation of ﬁbroblastoid cells to chondrocytes, whereas a decrease in PKCα expression causes
dedifferentiation of mature chondrocytes. In contrast, activation of ERK1/2 causes dedifferentiation and blocks differentiation and redifferentiation. p38 has been implicated as a positive
regulator of redifferentiation. PKC exerts its effects on differentiation by inhibiting ERK1/2 signalling, whereas PKC and ERK1/2 independently regulate dedifferentiation of chondrocytes.
The question mark indicates a hypothetic link between PKC and p38. See text for further details.
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inhibitor AG1478 [77]. Since selective inhibition of PKCαwas sufﬁcient
to inhibit in vitro chondrogenesis, it can be hypothesised that the
EGF-inducedmodulation of PKCα-dependent signalling is the key factor
of the inhibition of chondrogenesis by EGF. The schematic drawing in
Fig. 9 shows how IGF-1 and EGF exert their distinct functions in a
PKC-dependent manner during chondrogenesis.6.5. Crosstalk between JNK and PKC pathways
The third MAPK signalling pathway, the c-Jun N-terminal kinase
(JNK)—also known as the stress-activated protein kinase (SAPK)—
pathway is strongly activated by a multitude of noxious stimulants
such as heat shock, ionising radiation, oxidant stress, and mechanical
shear. However, in contrast to ERK1/2, the JNK pathway is not strongly
activated by growth factors and mitogens in the majority of cell types
studied [65]. Moreover, relative to the ERK1/2 and p38 pathways,
substantially less research has been carried out in searching for the
regulatory roles of JNK signalling during chondrogenesis. As previously
described, Oh and colleagues demonstrated that unlike ERK and p38,
the phosphorylation of JNK was not detectable during chondrogenesis
in micromass cultures of embryonic chick wing bud mesenchyme [8].
In accordancewith these observations, treatmentwith the JNK inhibitor
SP600125 did not inﬂuence cartilage matrix formation in micromass
cultures prepared from chick embryonic mesenchyme [65]. In contrast,
Hwang and co-workers described thatWnt-3a caused the expression of
c-Jun and its phosphorylation by JNK, resulting in activation of AP-1,
which in turn suppressed the expression of Sox9 [9].In chondrocytes, the effects of CCN2/connective tissue growth factor
(CCN2/CTGF) are known to promote both proliferation and differentia-
tion of chondrocytes via the ERK1/2, p38 and JNK MAPK pathways [78].
In terms of upstream kinases of this pathway, the involvement of
PKCα, PKCε and PKCζ, as well as PI-3K and PKA has been implicated to
promote the maturation, proliferation and terminal differentiation of
chondrocytes. Although application of the PKC inhibitor calphostin C
repressed all of the effects of CCN2 and it also exerted inhibitory effects
on the activation of p38 and ERK1/2, it had no effect on JNK activation,
which suggests that while PKC was shown to be the major secondary
messenger of CCN2-mediated signals, the PKC–p38 pathway was inde-
pendent of JNK signalling [78].
In contrast, based on the results of Kim and colleagues, a link could
be established between PKC and JNK signalling in chondrocytes [10].
They used a different approach: microRNAs (miRNAs). These small
regulatory RNAs have been implicated in various cellular processes
such as cell fate determination, cell death, and differentiation. In this
study, they investigated the role of miRNA-34a in the reorganisation of
the actin cytoskeleton, which is essential for chondrocyte differentiation
as previously discussed, and found that in chicken chondroprogenitor
cells treated with JNK inhibitor—which suppresses chondrogenic differ-
entiation—the expression level of miRNA-34a was upregulated. On the
other hand, blockade of miRNA-34a was associated with decreased
protein expression of RhoA, a known modulator of stress ﬁbre expres-
sion and consequent downregulation of stress ﬁbres, and recovery of
type II collagen expression [10]. Since miRNA-34a negatively modulates
reorganisation of the actin cytoskeleton, which is one of the essential
processes for establishing the chondrocyte phenotype; and since PKC is
a keymediator of actin cytoskeleton reorganisation, these results suggest
Fig. 9. Illustration of IGF-1 and EGF pathways which converge on and differentially regulate PKCα, a central signalling relay in chondrogenic cells. IGF-1 upregulates PI-3K and thus
activates PKCα, which promotes chondrogenesis as described earlier. EGF, on the other hand, inhibits chondrogenesis by blocking PKCα. The chondro-inhibitory effect of EGF could be
prevented by the EGFR blocker AG1478. Further details in text.
992 C. Matta, A. Mobasheri / Cellular Signalling 26 (2014) 979–1000a putative link between JNK, miRNA-34a and PKC—although further
studies are needed to conﬁrm this hypothesis.
7. Involvement of PKC in other pathways during chondrogenesis
Since many open questions remained, endeavours to decipher the
precise role of PKC isoforms in regulating cartilage formation have con-
tinued. Asmentioned above, the PKApathway has long been established
to be a positive regulator of in vitro chondrogenesis [79]. As an attempt
to ﬁnd cross-talk between PKA and PKC pathways, Yoon and colleagues
undertook to carry out further experiments. In that study, PKA was
found to regulate N-cadherin expression in differentiating chondrocytesby regulating PKCα: inhibition of PKAwithH89blocked the activation of
PKCα; moreover, inhibition or downregulation of PKC isoforms was all
accompanied by the same altered pattern of N-cadherin expression [21].
Furthermore, PKA was found to be an upstream regulator of PKCα as
selective inhibition of PKCs did not affect PKA activity (see Fig. 10).
As mentioned previously, PKCwas involved in mediating the effects
of glucose concentration in culture medium [68]. Since the glucose
effect has also been shown to have a profound effect on mesenchymal
stem cell (MSC) differentiation, Tsai and co-workers aimed to evaluate
the extent of chondrogenesis ofMSCs previously culturedwith different
concentrations of glucose [80]. In that study, MSCs maintained in high
glucose were less chondrogenic than low glucose maintained cells.
Fig. 10. PKC isoenzyme-dependent (primarily PKCα) regulation of cell adhesionmolecules (integrinα5β1, N-cadherin) that are essential for chondrogenesis. PKCα activity is required for
deactivation of ERK1/2, a negative regulator of chondrogenic differentiation in chicken limb bud-derivedmicromass cultures, which is in turn essential for themodulation of cell adhesion
molecule expression. PKA is an upstream activator for PKCα since its inhibition with H89 altered the signalling pathway. High concentrations of extracellular glucose also activate this
pathway and thus enhance chondrogenesis. By contrast, EGF negatively regulates this signalling since the EGFR blocker AG1478 prevented the negative effects of EGF. For a more detailed
explanation, please see text.
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phosphorylation of PKC and expression of type II TGF-β receptor.
Inhibiting the PKC activity of high glucose-maintained MSCs with
Gö6983 upregulated type II TGF-β receptor expression of chondrogenic
cell pellets and enhanced chondrogenesis. In summary, these data
suggest that the chondrogenic capacity of MSCs is modulated by
the glucose concentration of the medium in expansion culture via
PKC-dependent signalling, and that chondrogenesis induced in subse-
quent pellet culture can be enhanced by modulating PKC activity
(see Fig. 6) [80].
8. PKC-dependent regulation of chondrogenesis via cell
adhesion molecules
Early steps of chondrogenesis are widely accepted to be controlled
by cell-to-cell and cell-to-ECM interactions through coordinating
precartilage condensation and cartilage nodule formation. Several cell
adhesion molecules such as N-cadherin and integrins (integrin α5β1 in
particular) are reported to be involved in this process [74]. N-cadherin
expression is downregulated during progression from precartilage
condensation to cartilage nodule formation during chondrogenic differ-
entiation, and it is inversely correlated to that of type II collagen, suggest-
ing a determining role for this cell adhesion molecule. Based on the
central role of PKC signalling that is indispensable for chondrogenesis
to occur, several attempts have been made to establish a link between
PKC and cell adhesion molecules.
As previously mentioned, Chang and co-workers proposed that PKC
regulates chondrogenesis by modulating N-cadherin expression via
ERK-1 activity [67]. They demonstrated that inhibition of PKC activity by
Gö6976 or chronic exposure to PMA modulated the expression of celladhesion molecules (N-cadherin, integrin) involved in precartilaginous
condensation during early chondrogenesis, which was reversed by the
inhibition of ERK-1 by PD98059. From these data, the authors concluded
that ERK-1 regulates the expression of cell adhesion molecules and ECM
components in a PKC-dependent manner. To shed more light on this
pathway, Yoon and co-workers demonstrated that PKA, a quintessential
regulator of chondrogenesis, regulates N-cadherin expression in differen-
tiating chondrocytes through PKCα as inhibition of PKAwithH89 blocked
the activation of PKCα [21]. Furthermore, as discussed above, stimulation
of the EGF receptor blocked precartilage condensation and altered the
expression of cell adhesion molecules (N-cadherin and integrin α5β1)
by inhibiting the expression and activation of PKCα with concurrent
activation of ERK-1 and inhibition of p38; all these effects could be
blocked by the application of the EGF receptor inhibitor AG1478 [77].
The PKC-dependent regulation of key cell adhesion molecules was
also conﬁrmed by another study. As previously mentioned, Han and
co-workers observed that high concentrations of glucose signiﬁcantly
stimulated chondrogenesis [68]. They reported that glucose modulated
the expression patterns of cell adhesion molecules including ﬁbronec-
tin, integrin β1, and N-cadherin and concluded that by acting through
PKCα high doses of glucose induce the downregulation of ERK1/2 activ-
ity and stimulate chondrogenesis via modulating the expression of
adhesion molecules [68].
The above results indicate that PKC and ERK1/2 regulate the
expression of cell adhesion molecules during chondrogenesis of
mesenchymal cells. However, it turned out that during chondrocyte
de- and redifferentiation, their relationship is different. Yoon and co-
workers observed that the low levels of N-cadherin in differentiated rab-
bit articular chondrocytes dramatically increased as the differentiated
phenotype was lost by serial monolayer culture; upon redifferentiation
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the previous levels. However, inhibition of PKCwith long-term exposure
to PMA in chondrocytes cultured in monolayer did not affect N-cadherin
expression, nor did it alter N-cadherin levels in dedifferentiated cells
cultured in alginate gel [74]. These data collectively indicate that unlike
during the differentiation process, PKC (and ERK1/2) does not regulate
de- and redifferentiation of articular chondrocytes by altering the
expression of cell adhesion molecules.
The results of these studies on the role of PKC signalling inmediating
the expression of cell adhesion molecules during chondrogenesis are
shown in Fig. 10.
9. PKC signalling during pathological conditions
Shortly after the expression and activity of PKC isoenzymes have
been reported in model systems to study in vitro chondrogenesis,
attempts have beenmade to generate data on the role of PKCs in disease
progression. Osteoarthritis (OA), one of the ten most disabling diseases
in developed countries, is the most common form of musculoskeletal
disorders, mainly caused by age, genetic predisposition, obesity and
prior joint injuries. OA is characterised by inﬂammation and breakdown
of the shock-absorbing articular cartilage within the joint, and conse-
quently symptoms including pain, swelling, inﬂammation, bone spur for-
mation, and impairedmobility result [81]. To date, no effective or curative
treatment is available forOAother thanmanagement of painwith analge-
sics and inﬂammation with non-steroidal anti-inﬂammatory drugs
(NSAIDs). Current therapies are primarily targeted at reducing pain and
inﬂammation. Therefore, there is a pressing socio-economic need for
the development of therapeutic strategies to preserve the natural articu-
lar cartilage and its underlying bone. To achieve this, a better understand-
ing of the cellular background of the disease is inevitable. It is therefore
not surprising that considerable efforts have beenmade to identify alter-
ations in key signalling pathways such as PKC signalling in inﬂammatory
chondrocytes. Furthermore, the PKC signalling pathway is a major drug
target because several isoforms are important regulators of survival or
apoptosis, attempts have been made to establish a link between PKC
signalling and degenerative joint diseases.
9.1. PKC isoforms with altered expression patterns in healthy and OA
chondrocytes
One of the earliest publications in this ﬁeld by Satsuma and
colleagues in 1996 described altered expression patterns of various
PKC isoenzymes in healthy and mechanically induced OA chondrocytes
in rats [82]. They found that cells expressing PKCβ and PKCγ could only
be identiﬁed in healthy chondrocytes but not in sham-operated or OA
samples. Quite interestingly PKCα, which was only observed in the
subchondral bony layer in the controls, appeared in chondrocytes in
the superﬁcial and columnar layers of the osteoarthritic knee. Although
PKCε expression was detectable in chondrocytes of the superﬁcial
portion of the columnar layer in the control, signals for PKCε disap-
peared from the superﬁcial region of columnar layer and increased in
the middle of the columnar layer in early OA joints. However, as this
was just a descriptive study, the authors were unable to establish
whether the observed redistributions of PKC isoenzymes were signs
for initiating destructive processes, reﬂected attempted cell repair
mechanisms, or were simply a consequence of alterations in cellular
signalling pathways.
The same group continued their research interests and by using an
experimental model of slowly progressive osteoarthritis in rabbits, they
reported that intra-articular administration of the PKC-activatingphorbol
ester TPA almost completely blocked the progression of OA, whereas a
non-PKC-activating phorbol ester (phorbol-12,13-didecanoate, PDD)
failed to prevent OA [83]. In a different study, they once again observed
that PKCα could be detected in chondrocytes from experimentally
induced OA cartilage and that intra-articular administration of TPAprevented the development of the disease; furthermore, they also
provided evidence that PKC was involved in the stress-mediated degra-
dation of articular cartilage [84].
In contrast to these initial results, LaVallie and co-workers demon-
strated the presence of different PKC subtypes in arthritic chondrocytes
[51]. As discussed above, they were the ﬁrst to apply Affymetrix
GeneChip® to study differences in the transcriptome of healthy and
osteoarthritic cartilage samples. Of the four PKC isoenzymes detected
in human chondrocytes, only PKCζ appeared to be transcriptionally
altered in OA articular cartilage compared with normal articular carti-
lage, with an approximately 2.5–3.5-fold upregulation of transcript
levels in OA cartilage. Nevertheless, these observations served as a
basis of the chondroprotective hypothesis for PKC activation during
early stages of OA.
9.2. Molecular dissection of PKC signalling pathways in inﬂammatory
chondrocytes
In support of this theory, further experimentswere conducted. Since
one of the major factors in OA onset and progression is extensive
mechanical load on major weight bearing joints, Fukuda and co-
workers examined the effects of mechanical stress on chondrocyte me-
tabolism and the activity of PKC [85]. They reported that low frequency
andmagnitude of cyclic tensile stretch increased proteoglycan synthesis
in chondrocytes, whereas high frequency and magnitude loading
decreased this parameter. Moreover, in this condition, PKC activity
was reduced. The authors suggested the involvement of PKC in the
mechanical stress-mediated inhibition of proteoglycan synthesis, prob-
ably viamodulating the actin cytoskeleton.
Mediated primarily by cytokines such as IL-1, IL-17, and tumour
necrosis factor α (TNFα), inﬂammation is a major characteristic of
joint diseases such as OA, during which inﬂammatory mediators are
released by inﬁltrating immune cells. It is generally accepted that in
chondrocytes, the effects of these pro-inﬂammatory cytokines such as
IL-1 aremediated through NO production. NO regulates cartilage degra-
dation by causing dedifferentiation and apoptosis of chondrocytes via
activation of ERK1/2 andp38, respectively [86]. Since PKC plays a central
role in transducing signals that inﬂuence differentiation, survival and
apoptosis, Kim and colleagues investigated the molecular mechanisms
of how PKC isoforms regulate NO-induced dedifferentiation and
apoptosis of articular chondrocytes. Indeed, they found that activities
of PKCα and PKCζ were reduced during NO-induced dedifferentiation
and apoptosis; while the attenuated PKCα activity was independent of
ERK1/2 or p38, PKCζ activity was reduced as a result of NO-induced
p38 kinase activation [61]. Furthermore, the fact that inhibition of PKCα
and PKCζ activities potentiated NO-induced apoptosis, whereas ectopic
expression of these isoforms signiﬁcantly reduced the number of apopto-
tic cells and blocked dedifferentiation further supports the theory that
PKC isoforms are involved in mediating NO-induced signalling. Thus,
these results indicate that p38 kinase-independent and -dependent inhi-
bition of PKCα and PKCζ, respectively regulates NO-induced apoptosis
and dedifferentiation of articular chondrocytes [61]. Moreover, as p38
kinase also regulates NF-κB, Kim and Chun investigated the functional
relationship between PKC and NF-κB signalling in chondrocytes and
reported that although NO-stimulated NF-κB activation was inhibited
by ectopic PKCα and PKCζ expression, NO-induced inhibition of PKCα
and PKCζ activity was not affected by NF-κB inhibition, indicating that
NO-induced inhibition of PKCα and PKCζ activity was required for the
NF-κB activity that regulates apoptosis but not dedifferentiation in artic-
ular chondrocytes [87].
Kim and colleagues further dissected the molecular mechanism
regulating chondrocyte dedifferentiation and apoptosis by investigating
the effects of the actin cytoskeletal architecture on NO-induced dedif-
ferentiation and apoptosis in articular chondrocytes, with a focus on
ERK1/2, p38 and PKC signalling [62]. Disruption of the actin cytoskeleton
by cytochalasin D inhibited NO-induced apoptosis and dedifferentiation
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of p38 kinase and inhibition of PKCα and PKCζ. Furthermore, cytochalasin
D also suppressed downstream signalling of p38 kinase and PKC, such
as NF-κB activation and p53 accumulation, which are necessary for
NO-induced apoptosis. There results indicated that in accordance with
the above data, the actin cytoskeleton mediates NO-induced regulatory
effects in chondrocytes by modulating p38, as well as PKCα and PKCζ
[62] (see also Fig. 5).
IGF-1 is known to inhibit the catabolic effects of IL-1 on PG synthesis
in cartilage explants and suppresses the degradation of ECM compo-
nents by reducing matrix metalloproteinase-1 (MMP-1) and MMP-8
expression and activity. In addition, it has long been known that levels
of IGF-1 are enhanced in the synovial ﬂuid of OA patients [88], and
that the response of inﬂammatory chondrocytes to IGF-1 is reduced
[89], suggesting that IGF-1 is involved in the pathophysiology of OA.
Based on that, Oh and Chun examined the role of IGF-1 in NO-induced
dedifferentiation and apoptosis of articular chondrocytes and reported
that IGF-1 inhibits NO-induced dedifferentiation and apoptosis [76].
As mentioned earlier, IGF-1 induces chondrogenic differentiation via
the PI-3K–PKCα–p38 pathway (see also Fig. 9). In addition, they have
also shown that IGF-1 inhibits NO-induced dedifferentiation and apo-
ptosis of articular chondrocytes through the activation of PI-3K and by
conversely regulating p38, ERK1/2, as well as PKCα and PKCζ [76]. In
summary, the effects of IL-1 mediated through NO production regulate
differentiation, survival, and inﬂammatory responses by modulating
ERK1/2, p38, as well as PKCα and PKCζ in articular chondrocytes during
OA.
In terms of MMP-2 and MMP-9 secretion, Chu and co-workers
applied multiple inhibitors in early arthritic chondrocytes including
PKC inhibitors such as staurosporine, compound H7, and Gö6976 [90].
They demonstrated that the PKC inhibitors suppressed both MMP-2
and MMP-9 production in OA chondrocyte cultures, which implicate
that PKC signalling was involved in disease onset and progression in
early OA.
LaVallie and colleagues demonstrated that PKCζwas transcriptional-
ly upregulated in human OA articular cartilage clinical samples [51].
Furthermore, upon IL-1 treatment rapidly increased phosphorylation
of PKCζwas observed, implicating its activation and function in the sig-
nalling pathway. In primary chondrocytes, application of IL-1 and TNFα
increased NF-κB activity resulting in proteoglycan degradation, which
could be blocked by the PKC inhibitors RO31-8220, bisindolylmaleimide
I and Gö6976, but at the same time it was unaffected by calphostin C
that does not inhibit atypical PKCs including PKCζ. Moreover, either a
cell-permeable PKCζ pseudosubstrate peptide inhibitor or overexpres-
sion of a dominant negative PKCζ protein could prevent TNFα and
IL-1-mediated NF-κB activation and proteoglycan degradation. These
ﬁndings support the hypothesis that PKCζmay be an important signal-
ling component of cytokine-mediated cartilage ECMdegradation during
OA [51], in agreement with the results discussed above [62].
A year later, the same team further analysed the role of PKCζ in OA
onset and progression and reported that the phosphorylation of PKCζ
and NF-κB induced by treatment with IL-1 could be speciﬁcally blocked
by inhibitors of atypical PKCs [91]. Moreover, inhibition of PKCζ
suppressed IL-1-mediated upregulation of ADAMTS-4 and aggrecanase,
whereas inhibitors of atypical PKCs also blocked IL-1-induced NO
production and NOS2 mRNA expression, demonstrating a link between
PKCζ and NO production in OA chondrocytes. Furthermore, transient
knock-down of PKCζmRNA signiﬁcantly reduced both ADAMTS-4 and
NOS2mRNA expressions, indicating that PKCζ is involved in the regula-
tion of IL-1-induced NF-κB signalling in human OA chondrocytes [91].
Therefore, these results suggest that PKCζ regulates the production of
matrix-degrading enzymes as well as NO production in OA and may
have a profound effect on disease progression.
Asmentioned earlier, apart from PKCζ, PKCα has also been implicat-
ed as a major player in OA pathogenesis. To this end, Chen and
colleagues investigated the expression of PKCα in chondrocytes ofmedium or late stage human knee OA cartilage to further evaluate
their role in chondrocyte apoptosis during disease progression [92].
They provided further data in support of the early observations of Satsu-
ma and colleagues [82] in that the increased expression of PKCα was
involved in OA progression and apoptosis, and concluded that the
correlation between OA progression, the role of PKCα-dependent
signalling pathways, and chondrocyte apoptosis allows for new thera-
peutic strategies to be considered. The concept of PKC isotypes mediat-
ing OA onset and disease progression along with a suggested signalling
pathway and the scientiﬁc data in support of this hypothesis is shown in
Fig. 11.
10. Conclusions
In summary, it is evident that we are only at the beginning of under-
standing the precise role of PKC subtypes during chondrogenesis and
how they are regulated. Clearly, there are many yet unexplored ﬁelds
in this area; by exploiting these novel approaches and applying them
to not only healthy but also inﬂammatory chondrocytes may enable us
to halt or even reverse disease progression. Shedding more light on ex-
actly how PKC signalling pathways and Ca2+ homeostasis interact with
each other; or elucidating novel miRNA-mediated control mechanisms
would open new perspectives for a better understanding of healthy as
well as pathological differentiation processes of chondrocytes, and
may also lead to the development of new therapeutic approaches and
novel strategies for controlling the differentiation of MSCs.
11. Future directions
The formation of cartilage that makes up the majority of the verte-
brate skeleton at the beginningof embryonic development relies on adel-
icate sequence of interactions between differentiating chondroprogenitor
cells and a plethora of external stimuli such as various growth factors,
morphogens, hormones, cytokines, and many other ligands. We are
only beginning to understand the key pathways through which these
multiple stimuli are decoded and integrated to coordinate cellular
responses and changes in gene expression events that are characteristic
to the particular stage of chondrocyte maturation within the developing
multicellular organism. From the pieces of evidence we have reviewed
here, it is evident that PKC isoforms, especially PKCα, are central players
in these processes (Fig. 12). However, our current understanding of the
precisemechanisms throughwhichPKC signalling regulates chondrogen-
esis and chondrocyte function is still extremely limited.
11.1. PKC and Ca2+ signalling
Although the downstream components of PKC signalling during
chondrogenesis such as ERK1/2 and p38MAPK, cell adhesionmolecules,
changes in gene expression of key chondrogenic markers are relatively
well-known, current knowledge concerning signalling components lo-
cated upstream of PKC are only poorly characterised. Given that PKCα
is a prototypical member of the classic PKC isoenzymes, cytosolic Ca2+
should be considered as a major regulator. In general, cellular events
governed by Ca2+ require transiently elevated cytosolic Ca2+ concentra-
tion for Ca2+-sensitive signalling components to be activated [93]. There
are twomain sources of Ca2+ for initiating and generating signals; Ca2+
entry across the plasma membrane via either voltage-operated Ca2+
channels or agonist-dependent and voltage-independent Ca2+ entry
pathways; and Ca2+ release from internal stores such as the smooth
endoplasmic reticulum(ER) via the inositol-1,4,5-trisphosphate receptor
(IP3R) or the ryanodine receptor (RyR) [94]. Since changes of intracellu-
lar Ca2+ concentration are closely related to cell proliferation and differ-
entiation that are important functions of undifferentiated cells such as
chondroprogenitors or MSCs, the Ca2+ homeostasis of MSCs has been
thoroughly investigated [95]. Furthermore, Ca2+ dependent signalling
pathways are also key factors that govern chondrogenesis [96].
Fig. 11. PKCα and PKCζ are key components in signalling pathways that are suggested to be involved in OA pathogenesis and progression. NO is a key mediator liberated during inﬂam-
matory processes, whose production is enhanced by TNFα and IL-1, but blocked by cytochalasin D-induced cytoskeletal rearrangement. The effects of IL-1 could be blocked by the IGF-1
pathway. Nitric oxide exerts its detrimental effects such as chondrocyte apoptosis and dedifferentiation, as well as activation of cartilage ECM degrading enzymes (MMP-2, MMP-9,
ADAMTS-4, aggrecanase) via signalling that involves p38 MAPK, PKCα and PKCζ, NF-κB and p53. Furthermore, this pathway activates NOS2 that is involved in NO generation. Please
see text for a more detailed explanation and references.
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intracellular free Ca2+ concentration play distinct roles in the regulation
of various cellular processes. The same applies to in vitro chondrogene-
sis;we have reported that a distinct pattern of cytosolic Ca2+ concentra-
tion was required for the differentiation of chicken limb bud-derived
mesenchymal cells in micromass cultures; this parameter was found
to be very precisely regulated in chondroprogenitor cells since altering
resting Ca2+ levels by either A23187 Ca2+ ionophore or EGTA over or
below certain threshold values abrogated chondrogenesis [97]. Further-
more, we managed to establish a correlation between basal cytosolic
Ca2+ concentration and activity of the Ca2+–calmodulin dependent
phosphoprotein phosphatase calcineurin, a key regulator of in vitro
chondrogenesis in chicken limb bud-derived micromass cultures.
Conversely, inhibition of calcineurin by cyclosporine-A altered resting
Ca2+ levels in differentiating chondroprogenitors, implicating a recipro-
cal regulation between Ca2+ homeostasis and Ca2+-sensitive effector
proteins [97].
Although in that study, we have not looked at how PKC activity
might be modulated by altered basal intracellular Ca2+ levels, nor did
we investigate if there was an effect of selective inhibition of PKCα on
the Ca2+ homeostasis, it would be interesting to establish such a link
during chondrogenesis. Since according to Sonn and Solursh, PKC activ-
ity was initially low but signiﬁcantly increased during the course
of chondrogenesis in limb bud-derived HDC [42]; furthermore, we
found that there is a rise in resting intracellular Ca2+ levels duringchondrogenesis, we can speculate that changes in PKC activity can at
least partially be attributed to the characteristic pattern of basal Ca2+ con-
centration and conversely, how PKC activity may modulate basal Ca2+
levels. In fact, such a correlation has long been known to exist in Jurkat
T cells in which a PKC-sensitive Ca2+ extrusion mechanism has been re-
ported; furthermore, Balasubramanyam and Gardner described that acti-
vation of PKCmodulated intracellular Ca2+ levels by both inhibiting Ca2+
inﬂux and by stimulating Ca2+ extrusion [98]. In vascular smoothmuscle
cells, the potent vasoconstrictor substances 5-hydroxytryptamine, angio-
tensin II, and bradykinin that bind to G-protein coupled receptors and ac-
tivate PLC-β induced a transient increase in intracellular calcium Ca2+
and at the same time brought about a rapid but transient activation of
the calcium sensitive PKCα, which resulted in increased proliferation
rate [99]. In concert with these ﬁndings, an increase in cytosolic Ca2+
levels and concurrently elevated PKC activity may act cooperatively on
the myogenic contraction of skeletal muscle arteries [100]. Correlation
between increased free cytosolic Ca2+ levels and enhanced PKC activity
has also been found in rat cerebrocortical presynaptic nerve terminals
[101]. Sohen and co-workers reported that in chondrocytes, the activa-
tion of the histamine H1 receptor led to stimulation of proteoglycan syn-
thesis and evoked increases of intracellular Ca2+ levels and that PKC
activity was also enhanced parallel to H1 receptor activation; moreover,
PKC inhibitors antagonised histamine-stimulated proteoglycan synthesis,
which suggested that PKC signalling was involved in H1 receptor-
mediated stimulation of proteoglycan synthesis in mature articular
Fig. 12. Summary of upstream modulators and downstream effectors of PKC signalling during chondrogenesis. Putative factors upstream and/or downstream of PKC that have not been
conﬁrmed in differentiating chondroprogenitors are shown with a question mark. (CAM, cell adhesion molecules).
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two pivotal regulators of chondrogenesis, i.e. PKC signalling pathways
and Ca2+ homeostasis, are interconnected with each other during
chondrogenic differentiation.
12. PKC as a molecular decoder of Ca2+ oscillations
Besides a stable rise, periodic oscillatory changes of cytosolic Ca2+
concentration also represent a nearly universal signalling mechanism
even in non-excitable cells [103]. Depending on the frequency and
amplitude of the Ca2+ transients, Ca2+ oscillations are known to control
cellular differentiation via activating different Ca2+-dependent tran-
scription factors including nuclear factor of activated T lymphocytes
(NFAT), NF-κB, JNK1, and CREB [104], most of which are key regulators
of chondrogenic differentiation. In our previous studies, we analysed in-
tracellular Ca2+ dynamics in individual chondroprogenitor cells at high
spatial and temporal resolution and established that differentiating cells
in chondrifying chickenmicromass cultureswere characterised by rapid
spontaneous Ca2+ oscillations modulated by voltage gated potassium
channel (KV)-driven membrane potential changes as well as voltage
gated Ca2+ channels [105,106]. Apart from voltage operated ion chan-
nels in the plasma membrane, contribution from the internal Ca2+
stores was also indispensable to these spontaneous Ca2+ events as
blockade of store-operated Ca2+ entry (SOCE) abolished repetitive
Ca2+ transients and abrogated in vitro chondrogenesis primarily via
reducing proliferation rate, suggesting a key regulatory role of these
processes [105].
That classic PKC isoforms can act as a molecular decoding machine
for Ca2+ signals has long been known; it has been reported that the
frequency of Ca2+ spikes can tightly control the extent and timing of
PKC activation in rat basophilic leukaemia 2H3 cells [27]. Interestingly,it has also been found that maximal and persistent PKC activation
could only be reachedwhenhigh-frequency Ca2+ oscillationswere con-
currently present. This enables us to speculate that such a scenario could
exist in differentiating chondroprogenitors; given that altering the am-
plitude and frequency of spontaneous Ca2+ spikes leads to abrogation
of in vitro chondrogenesis, one of the possible downstream effectors of
Ca2+ oscillations could be the activation of classic PKC subtypes.
Although this putative link between repetitive Ca2+ signals and PKC ac-
tivation has not been tested during early steps of chondrogenesis, it
would be intriguing to see how modulation of such Ca2+ events affect
PKC activation and conversely, how various parameters of Ca2+ spikes
are modulated following administration of PKC inhibitors. There is evi-
dence that PKC is involved in the regulation of ATP-triggered Ca2+ oscil-
lations in chicken granulosa cells; PKC appeared to be a central player in
these Ca2+ events as oscillations were prevented by either full activa-
tion or inhibition of PKC activity [107].
13. Ion channels as downstream targets of PKC
Although chondrocytes are non-excitable cells, their plasma mem-
brane contains a rich complement of ion channels including a range of
potassium channels (KATP, BK, KV, and SK), sodium channels (epithelial
sodium channels, voltage activated sodium channels), transient recep-
tor potential calcium channels, various non-selective cation channels,
chloride channels, which are collectively referred to as the chondrocyte
channelome [108]. However, the function of these ion channels is less
well understood; chondrogenesis, mechanotransduction, cell volume
regulation, and apoptosis all appear to involve the function of ion chan-
nels and thus their function is indispensable to chondrocyte function
[109]. Therefore, modulation of chondrocyte ion channel activity is of
central importance for cartilage formation and maintenance. PKC has
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K+ channels and KATP channels [110,111], and modulates voltage gated
K+ [112], Ca2+ [113], and Cl2− channels [114]. Apart from bona ﬁde
ion channels, PKC activity has been reported to be required for SOCE in
human glomerular mesangial cells, since the thapsigargin-induced
Ca2+ entry pathway was abolished by the PKC inhibitor calphostin C,
whereas the PKC activator PMA enhanced Ca2+ inﬂux [115]. However,
since the molecular identity of the SOC channel has not been revealed
at that time, they were unable to unequivocally identify the protein
whose phosphorylation was required for SOCE.
Although themechanism of SOCE has long been known, themolecu-
lar identity of the channel-forming proteins was revealed only recently
[116]. SOCE is initiated by oligomerisation of the Ca2+ sensor stromal in-
teraction molecules STIM1 and STIM2 in the endoplasmic reticulum
(ER) membrane, triggered by a decrease in the Ca2+ content below a
certain threshold level. Once oligomerised, STIM1/STIM2 is redistributed
into distinct puncta in the ER membrane that are located in close prox-
imity to the plasmamembrane, where STIM interacts with Orai1 dimers
enabling them to form tetramers, thus giving rise to the functional Ca2+
channel. SOCE has been shown to be indispensable for chondrogenesis
to take place as administration of SOCE inhibitors abrogated cartilage
matrix formation in micromass cultures; furthermore, SOCE was
also required for repetitive Ca2+ oscillations, a phenomenon that was
found to be necessary for the differentiation of chondroprogenitor cells
[105]. However, the regulation of SOC channels is largely unknown. It
was not until 2010 that Kawasaki and colleagues suggested a mecha-
nism by which PKC regulates SOCE in HEK293 cells. In that study, they
demonstrated that PKC suppressed SOCE by phosphorylating Orai1 at
N-terminal Ser-27 and Ser-30 residues, since application of PKC inhibi-
tors and knockdown of PKCβ both resulted in increased Ca2+ inﬂux
[117]. The fact that Ma and co-workers found that PKC activation was
required for SOCE in mesangial cells contradicts with the ﬁndings of
Kawasaki and colleagues who found that phosphorylation of Orai1 by
PKC suppressed Ca2+ entry might be resolved by assuming that regula-
tion of SOCE by PKC is likely to be dependent on the PKC isoforms and
types of SOC channels expressed in any given cell type. Therefore, it
would be intriguing to investigate whether PKC is involved in the regu-
lation of SOCE in differentiating chondroprogenitor cells and thus mod-
ulate Ca2+ oscillations to promote chondrogenesis.
14. miRNA-mediated PKC regulation of chondrogenesis
Apart from Ca2+ signalling, there are other pathways potentially
involved in mediating PKC activity during chondrogenesis. One such
possibility might be regulation through miRNAs, which are evolution-
arily conserved small non-coding RNAs that modulate gene expression
and play important roles in diverse biological functions, including cell
differentiation (for a relevant recent review, see [118]). Recent studies
have indicated that miRNAs play important roles in tissue morphogen-
esis, and increasing evidence indicates that miRNAs are an integral part
of the regulatory network in chondrocyte differentiation and cartilage
function. In particular, miRNA-145 was reported to downregulate
Col2a1, Acan1, COMP, Col9a2, and Col11a1, and reduces GAG content
during chondrogenic differentiation of MSCs, which indicate that
miRNA-145 is a key negative regulator of chondrogenesis, directly
targeting Sox9 at an early stage of the process [119]. The laboratory of
Jin has been carrying out research that also identiﬁed miRNAs as key
regulators of various steps of chondrogenesis ranging from mainte-
nance of cartilage integrity [120], migration of chondroprogenitor cells
[121], cytoskeletal dynamics [10], and also during osteoarthritis [122];
in fact, based on the results of this group and others,miRNAs are emerg-
ing new targets for OA.
As mentioned above, miRNA-34a has been reported to negatively
modulate reorganisation of the actin cytoskeleton, which is essential
for establishing chondrocyte-speciﬁc morphology [10]. We herein
discussed earlier that PKC signallingwas central tomediating the effectsof cytoskeletal reorganisation during chondrogenesis, as well as chon-
drocyte re- and dedifferentiation. Assuming that both miRNA and PKC
signalling converge on the actin cytoskeleton, it would be logical to
hypothesise anmiRNA-mediated control of PKC. Although such a regula-
tory pathway has not been reported in chondrocytes, miRNA-mediated
regulation of PKC activity [123] and conversely, PKC-controlled miRNA
activity [124] has been demonstrated in other systems. Given that
other kinases, PKA in particular, have been found to be regulated by
miRNA-23b during chondrogenesis in MSCs [125], it is plausible to as-
sume that such regulation for PKC subtypes also exists.
14.1. Implications of PKC and its modulation for tissue engineering
applications
Due to theirmultipotent nature, hMSCs are increasingly being consid-
ered for clinical therapeutic applications, such as bone and cartilage
tissue engineering. However, current differentiation protocols require
further optimisation before they can be translated into the clinical prac-
tice. To achieve this, a deeper understanding of signalling pathways
that control lineage-speciﬁc differentiation is inevitable to enable
targeted manipulation and exploitation, which may enhance the quality
of tissue engineered constructs. Given that PKC is a key regulator in
chondroprogenitors, it can be a potential candidate to be targeted during
hMSC differentiation. In fact, inhibition of conventional PKCs and activa-
tion of the novel PKCδ during osteogenic differentiation of hMSCs
enhanced osteogenic differentiation both in vitro and in vivo [126]. Santos
and colleagues reported that in adipose-derived stem cells (ADSCs)
Wnt5a induced osteogenic differentiation via activation of the non-
canonical Wnt signalling pathway by increasing PKC activity [127]. In a
good correlation with these data, Park and Patel recently reported that
overexpression of the PKCδ isoform in ADSCs resulted in a marked
upregulation of cardiomyogenic genes such as Mef2C, cardiac actin and
troponin, which indicates that PKCδ activation is a key regulator of
cardiomyocyte formation [128]. PKC activationwas also required to stim-
ulate neurogenic differentiation of human stem cells of dental origin
[129]. These important data suggest that targeted manipulation of PKC
signalling pathways should be exploited to enhance the differentiation
fate ofMSCs, albeit further studies are needed to conﬁrm the applicability
of this approach in cartilage tissue engineering.
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